Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next‐Generation Sequencing Panel. (5th May 2014)

• Record Type: Journal Article
• Authors: Johnson, Douglas B.; Dahlman, Kimberly H.; Knol, Jared; Gilbert, Jill; Puzanov, Igor; Means‐Powell, Julie; Balko, Justin M.; Lovly, Christine M.; Murphy, Barbara A.; Goff, Laura W.; Abramson, Vandana G.; Crispens, Marta A.; Mayer, Ingrid A.; Berlin, Jordan D.; Horn, Leora; Keedy, Vicki L.; Reddy, Nishitha M.; Arteaga, Carlos L.; Sosman, Jeffrey A.; Pao, William
• Is Part Of: Oncologist. Volume 19:Number 6(2014)
• Page Start: 616
• Page End: 622
• Publication Date: 2014-05-05
• Subjects: Next‐generation sequencing -- Genotype -- Precision medicine -- Molecular targeted therapy -- Cancer -- Mutation; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2014-0011
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Background: Oncogenic genetic alterations "drive" neoplastic cell proliferation. Small molecule inhibitors and antibodies are being developed that target an increasing number of these altered gene products. Next‐generation sequencing (NGS) is a powerful tool to identify tumor‐specific genetic changes. To determine the clinical impact of extensive genetic analysis, we reviewed our experience using a targeted NGS platform (FoundationOne) in advanced cancer patients. Patients and Methods: We retrospectively assessed demographics, NGS results, and therapies received for patients undergoing targeted NGS (exonic sequencing of 236 genes and selective intronic sequencing from 19 genes) between April 2012 and August 2013. Coprimary endpoints were the percentage of patients with targeted therapy options uncovered by mutational profiling and the percentage who received genotype‐directed therapy. Results: Samples from 103 patients were tested, most frequently breast carcinoma (26%), head and neck cancers (23%), and melanoma (10%). Most patients (83%) were found to harbor potentially actionable genetic alterations, involving cell‐cycle regulation (44%), phosphatidylinositol 3‐kinase‐AKT (31%), and mitogen‐activated protein kinase (19%) pathways. With median follow‐up of 4.1 months, 21% received genotype‐directed treatments, most in clinical trials (61%), leading to significant benefit in several cases. The most common reasons for not receiving genotype‐directed therapy were selection of standard therapy (35%) and clinical deterioration (13%). Conclusion: Mutational profiling using a targeted NGS panel identified potentially actionable alterations in a majority of advanced cancer patients. The assay identified additional therapeutic options and facilitated clinical trial enrollment. As time progresses, NGS results will be used to guide therapy in an increasing proportion of patients. Abstract : To determine the clinical impact of extensive genetic analysis, the use of a targeted next‐generation sequencing (NGS) platform (FoundationOne) in advanced cancer patients was reviewed. Mutational profiling using a targeted NGS panel identified potentially actionable alterations in a majority of the patients. The assay identified additional therapeutic options and facilitated clinical trial enrollment. As time progresses, NGS results will be used to guide therapy in an increasing proportion of patients.